

Pilar Vizcarra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1702777/publications.pdf>

Version: 2024-02-01

34
papers

687
citations

840119

11
h-index

610482

24
g-index

37
all docs

37
docs citations

37
times ranked

1277
citing authors

#	ARTICLE	IF	CITATIONS
1	Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. <i>Lancet HIV</i> , 2020, 7, e554-e564.	2.1	279
2	Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. <i>HIV Medicine</i> , 2021, 22, 372-378.	1.0	123
3	Efficacy and Safety of Dolutegravir plus Boosted-Darunavir Dual Therapy among Highly Treatment-Experienced Patients. <i>Antiviral Therapy</i> , 2019, 24, 467-471.	0.6	20
4	Weight gain in people living with HIV switched to dual therapy. <i>Aids</i> , 2020, 34, 155-157.	1.0	18
5	Carbapenemase-producing <i>Enterobacterales</i> infections in COVID-19 patients. <i>Infectious Diseases</i> , 2022, 54, 36-45.	1.4	18
6	Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting. <i>HIV Research and Clinical Practice</i> , 2019, 20, 64-72.	1.1	15
7	Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers. <i>Emerging Microbes and Infections</i> , 2021, 10, 493-496.	3.0	15
8	CD4/CD8 ratio improvement in HIV-1-infected patients receiving dual antiretroviral treatment. <i>International Journal of STD and AIDS</i> , 2019, 30, 656-662.	0.5	14
9	COVID-19 and geographical area of origin. <i>Clinical Microbiology and Infection</i> , 2021, 27, 632.e1-632.e5.	2.8	14
10	T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity. <i>Clinical and Translational Immunology</i> , 2021, 10, e1341.	1.7	14
11	COVID-19 in HIV-Infected Individuals: Preliminary Results of a Prospective Cohort. <i>SSRN Electronic Journal</i> , 0, , .	0.4	14
12	BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity. <i>Vaccine</i> , 2021, 39, 7367-7374.	1.7	14
13	Metabolic Snapshot of Plasma Samples Reveals New Pathways Implicated in SARS-CoV-2 Pathogenesis. <i>Journal of Proteome Research</i> , 2022, 21, 623-634.	1.8	14
14	Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine. <i>HIV Medicine</i> , 2019, 20, 648-656.	1.0	12
15	Expansion of CD56dimCD16neg NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients. <i>Viruses</i> , 2022, 14, 46.	1.5	12
16	SARS CoV-2 infections in healthcare workers with a pre-existing T-cell response: a prospective cohort study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 916.e1-916.e4.	2.8	11
17	IFN- γ cell response and IFN- γ release concordance after in vitro SARS-CoV-2 stimulation. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13636.	1.7	11
18	Progressive and Parallel Decline of Humoral and T-Cell Immunity in Convalescent Healthcare Workers with Asymptomatic or Mild-to-Moderate Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 241-245.	1.9	10

#	ARTICLE	IF	CITATIONS
19	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S8-S19.	1.9	8
20	Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2. <i>Vaccine: X</i> , 2022, 11, 100165.	0.9	8
21	Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2. <i>Journal of Infection</i> , 2022, 85, 86-89.	1.7	7
22	Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients. <i>International Journal of STD and AIDS</i> , 2020, 31, 467-473.	0.5	5
23	Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity. <i>Frontiers in Microbiology</i> , 2021, 12, 812729.	1.5	5
24	Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy. <i>Infectious Diseases</i> , 2020, 52, 202-206.	1.4	4
25	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1955-1960.	1.3	4
26	Implementation of a lung cancer screening initiative in HIV-infected subjects. <i>PLoS ONE</i> , 2021, 16, e0260069.	1.1	4
27	Risk of SARS-CoV-2 Reinfections in a Prospective Inception Cohort Study: Impact of COVID-19 Vaccination. <i>Journal of Clinical Medicine</i> , 2022, 11, 3352.	1.0	3
28	Symtuza® (DRV/c/FTC/TAF) en la práctica clínica. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 31-36.	0.3	2
29	Stroke and Systemic Thromboembolism Prevention in People Living With Human Immunodeficiency Virus With Atrial Fibrillation: A Review of Its Implications for Clinical Practice. <i>CJC Open</i> , 2019, 1, 245-255.	0.7	2
30	Evaluation of the fracture risk assessment tool for determining bone disease and the impact of secondary causes of osteoporosis in people living with HIV. <i>HIV Research and Clinical Practice</i> , 2020, 21, 63-71.	1.1	2
31	Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1046-1050.	1.3	2
32	Progression Risk in People with HIV and COVID-19: Predictive Performance of Current Risk Scores. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 613-619.	0.5	2
33	Prevalencia de baja masa ósea en pacientes con infección por VIH. <i>Medicina Clínica</i> , 2021, 157, 234-237.	0.3	0
34	Prevalence of low bone mass in individuals with HIV infection. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 234-237.	0.1	0